<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444678</url>
  </required_header>
  <id_info>
    <org_study_id>NYU# 04-10 H11817</org_study_id>
    <secondary_id>CA225056</secondary_id>
    <nct_id>NCT00444678</nct_id>
  </id_info>
  <brief_title>Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of Cetuximab Plus Biweekly Capecitabine and Oxaliplatin (C-CO2) in the Treatment of Patients With KRAS Wild Type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open label, non-randomized study in subjects with histologically
      confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who
      have not received prior chemotherapy for metastatic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current treatment options for metastatic colon cancer are in need of further improvement.
      The three-drug combination of oxaliplatin with 5-FU/LV (fluorouracil/leucovorin) in the
      second-line treatment of metastatic colorectal cancer have shown a significant increase in
      response rate compared to 5-FU/LV alone. Oxaliplatin has recently been FDA-approved for this
      indication and is now a standard first-line agent in combination with a fluoropyrimidine.
      Cetuximab, a chimeric monoclonal antibody against the growth factor receptor, has shown
      activity with and without irinotecan in subjects with colorectal cancer refractory to
      irinotecan alone. Cetuximab has also been shown to be safe and effective when administered
      with infusional 5-FU/folinic acid plus irinotecan. These results suggest that the addition of
      cetuximab to fluoropyrimidine/oxaliplatin-based regimen in the 1st line setting should be
      explored. The use of the oral fluoropyrimidine, capecitabine, to replace infusional 5FU has
      been widely used for improved convenience and possible safety. We have chosen a modified
      biweekly CapeOx (capecitabine plus oxaliplatin) regimen due to its improved tolerance and
      response rate with a fixed dose of capecitabine given its widespread practice and ease of
      use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1, 2004</start_date>
  <completion_date type="Actual">June 1, 2015</completion_date>
  <primary_completion_date type="Actual">August 1, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate for the Combination Treatment</measure>
    <time_frame>6 months since the start of treatment</time_frame>
    <description>The tumor response rate (RR) will be defined as the total number of subjects whose best response is partial response (PR) or complete response (CR) during the first six months of treatment, divided by the number of subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Rates</measure>
    <time_frame>1 year since the first treatment and every year after for up to 10 years</time_frame>
    <description># of subjects who experienced &gt;= grade 1 adverse event that is positively related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>6 months since the start of treatment and every 3 months after treatment for up to 10 years</time_frame>
    <description>Time to Treatment Failure (progression or death) will be defined as the time from the first day of treatment until the date Progressive Disease (PD) or death is first reported. Subjects who die without a reported prior progression will be considered to have progressed on the day of their death. Subjects who did not progress will be censored at the day of their last tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months since the start of treatment and every 3 months after treatment for up to 10 years</time_frame>
    <description>Survival will be defined as the number of days from the first day of therapy to the date of death. If the subject is lost to follow-up, survival will be censored on the last date the subject was known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Cetuximab, Capecitabine and Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg/m2, IV every two weeks</description>
    <arm_group_label>Cetuximab, Capecitabine and Oxaliplatin</arm_group_label>
    <other_name>Erbitux</other_name>
    <other_name>C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m2, IV, q 2 weeks</description>
    <arm_group_label>Cetuximab, Capecitabine and Oxaliplatin</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2500 mg, po bid x 7 days every two weeks</description>
    <arm_group_label>Cetuximab, Capecitabine and Oxaliplatin</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have signed an approved informed consent.

          -  Histologically confirmed diagnosis of advanced adenocarcinoma of the colon or rectum,
             with KRAS wild type on mutational analysis.

          -  No prior chemotherapy for metastatic disease (chemotherapy naive). Prior adjuvant
             therapy with 5FU/LV or IFL (irinotecan, fluorouracilis, and leucovorin (folinic acid))
             permitted if completed at least six months prior to entering this study.

          -  Measurable disease by RECIST criteria as defined in Section 3.3.1.

          -  Subjects for whom tumor tissue is available for IHC ( Immunohistochemistry) testing
             for EGFR expression.

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status 0-1.

          -  Recovery in full from any previous surgical procedure.

          -  Expected survival greater than 12 weeks.

          -  Subjects at least 18 years of age.

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the
             study in such a manner that the risk of pregnancy is minimized. WOCBP must have a
             negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent
             units of HCG) within 72 hours prior to the start of study medication.

          -  Adequate hematologic function defined by an absolute neutrophil count (ANC) &gt;
             1,500/mm3, a platelet count &gt; 100,000/mm3 .

          -  Adequate hepatic function defined by a total bilirubin level no greater than 2.0 times
             the upper limit of normal (ULN) and AST (Aspartate Aminotransferase) and ALT (alanine
             transaminase) levels noo greater than 2.5 times the ULN (AST and ALT levels no greater
             than 5 times the ULN in the presence of liver metastases).

          -  Adequate renal function defined by a serum creatinine level no greater than 1.5 times
             the ULN.

        Exclusion Criteria:

          -  WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for
             the entire study period and for up to 4 weeks after the study.

          -  Women who are pregnant or breastfeeding.

          -  Women with a positive pregnancy test on enrollment or prior to study drug
             administration.

          -  Sexually active fertile men not using effective birth control if their partners are
             women of child-bearing potential.

          -  Subjects with &gt; Grade 1 neuropathy.

          -  Any active or uncontrolled infection.

          -  History of myocardial infarction within the previous six months or current clinical
             evidence of congestive heart failure.

          -  History of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of
             the cervix) unless in complete remission and off all therapy for that cancer for at
             least 5 years.

          -  Central nervous system metastases.

          -  Pregnant or lactating women. Men and women of reproductive potential must agree to use
             an effective contraceptive method.

          -  Medical or psychiatric disorders that would interfere with informed consent or make
             them a poor risk for participation in this trial.

          -  Prior allergic reaction to chimerized or murine monoclonal antibody therapy or
             documented presence of human anti-mouse antibodies (HAMA).

          -  Subjects receiving a prior investigational agent within 30 days.

          -  Prior therapy with oxaliplatin, cetuximab, or prior therapy that targets the EGF (
             epidermal growth factor) pathway.

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for
             treatment of either a psychiatric or physical (e.g., infectious disease) illness must
             not be enrolled into this study.

          -  Mutation in the KRAS gene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <results_first_submitted>February 18, 2020</results_first_submitted>
  <results_first_submitted_qc>April 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 3, 2020</results_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Previously untreated metastatic colorectal cancer</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>combined therapy</keyword>
  <keyword>biologics therapy</keyword>
  <keyword>antibody</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>EGFR</keyword>
  <keyword>epidermal growth factor receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab, Capecitabine and Oxaliplatin</title>
          <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab, Capecitabine and Oxaliplatin</title>
          <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="37" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate for the Combination Treatment</title>
        <description>The tumor response rate (RR) will be defined as the total number of subjects whose best response is partial response (PR) or complete response (CR) during the first six months of treatment, divided by the number of subjects.</description>
        <time_frame>6 months since the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Capecitabine and Oxaliplatin</title>
            <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate for the Combination Treatment</title>
          <description>The tumor response rate (RR) will be defined as the total number of subjects whose best response is partial response (PR) or complete response (CR) during the first six months of treatment, divided by the number of subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Rates</title>
        <description># of subjects who experienced &gt;= grade 1 adverse event that is positively related to treatment.</description>
        <time_frame>1 year since the first treatment and every year after for up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Capecitabine and Oxaliplatin</title>
            <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Rates</title>
          <description># of subjects who experienced &gt;= grade 1 adverse event that is positively related to treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to Treatment Failure (progression or death) will be defined as the time from the first day of treatment until the date Progressive Disease (PD) or death is first reported. Subjects who die without a reported prior progression will be considered to have progressed on the day of their death. Subjects who did not progress will be censored at the day of their last tumor assessment.</description>
        <time_frame>6 months since the start of treatment and every 3 months after treatment for up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Capecitabine and Oxaliplatin</title>
            <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to Treatment Failure (progression or death) will be defined as the time from the first day of treatment until the date Progressive Disease (PD) or death is first reported. Subjects who die without a reported prior progression will be considered to have progressed on the day of their death. Subjects who did not progress will be censored at the day of their last tumor assessment.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275" lower_limit="43" upper_limit="2822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Survival will be defined as the number of days from the first day of therapy to the date of death. If the subject is lost to follow-up, survival will be censored on the last date the subject was known to be alive.</description>
        <time_frame>6 months since the start of treatment and every 3 months after treatment for up to 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab, Capecitabine and Oxaliplatin</title>
            <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival will be defined as the number of days from the first day of therapy to the date of death. If the subject is lost to follow-up, survival will be censored on the last date the subject was known to be alive.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417" lower_limit="43" upper_limit="4166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab, Capecitabine and Oxaliplatin</title>
          <description>Cetuximab: 500 mg/m2, IV every two weeks
Oxaliplatin: 85 mg/m2, IV, q 2 weeks
Capecitabine: 2500 mg, po bid x 7 days every two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrage/ Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Vasovagal Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>(Arrhythmia)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Obstruction - Gi</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Disease progression on study</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness Of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular/Arrhythmia-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ascites (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea - patients with a colostomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea - patients without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fistula-intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin-Other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deirdre Cohen, MD</name_or_title>
      <organization>NYU Langone Health</organization>
      <phone>212-731-5656</phone>
      <email>Deirdre.Cohen@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

